Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen R&D Unveils Three New Research Platforms

This article was originally published in The Pink Sheet Daily

Executive Summary

With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.


Related Content

Bioqube Takes The Reins At J&J Innovation's JLINX
J&J's Van Hoof Talks About Expanding Vaccines Development
Big Pharma Embraces Microbiome Research; Partnering Poised To Follow
Janssen’s Bold Vision For A Microbiome Institute
California Dreaming: J&J Builds Bay Area Ties With Second Startup Home
Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan
Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts